Stephen Frye, Ph.D.

Fred Eshelman Distinguished Professor, Director, Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy

Stephen V. Frye, Ph.D., is currently the Fred Eshelman Distinguished Professor and Director, Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.  As director of the Center for Integrative Chemical Biology and Drug Discovery at UNC, Dr. Frye plays a key role in translational research through collaborative drug discovery projects with other UNC faculty. In addition, his Center has initiated a program in the area of chemical biology of chromatin regulation. Dr. Frye has a broad background in drug discovery and development having co-invented a marketed product himself (Avodart) and created a department that discovered the FDA approved kinase inhibitor oncology therapies, Lapatinib and Pazopanib, while at GSK. Since joining UNC in 2007, Dr. Frye’s Center has been designated as one of the National Cancer Institute’s chemical biology centers.  Additionally, the Center has published the first papers on small molecule ligands for methyl-lysine binding domains, and developed an international network of collaborators to increase the annotation and utility of UNC chromatin directed chemical probes. Dr. Frye has extensive experience in leading collaborative science at the national and international level having been the world-wide VP of Discovery Medicinal Chemistry while at GSK and more recently by contributing to the chemical probe discovery efforts of the Structural Genomics Consortium in Toronto and Oxford. Dr. Frye serves on several non-profit Boards including: Chair of Cancer Research UK’s Drug Discovery Committee; Member of A*STAR Project Review Committee of the Experimental Therapeutics Center, Singapore; Co-Founder and Vice President of the Academic Drug Discovery Consortiun; and Member of the SAB for the Spanish National Cancer Research Centre. Dr. Frye received his Ph.D. in organic chemistry from UNC Chapel Hill under the mentorship of the late Prof. Ernest Eliel. He is the author of over 100 patents and publications.

 


Back To Team

© Petra Pharma Corporation